New and Updated Clinical Dengue Vaccine Trials

Serological Study of Dengue and Characterization of Immune Response in Ten Endemic and Non-Endemic Cities in Mexico

Jul 1, 2021 | 18:00 pm

Condition: DengueIntervention: Diagnostic Test: Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengueSponsors: Mexican Society of Public Health; Merck Sharp & Dohme Corp.Not yet recruiting

Evaluation of Safety and Immunogenicity of a T-Cell Priming Peptide Vaccine Against Dengue

Jun 23, 2021 | 18:00 pm

Condition: DengueInterventions: Biological: LD vehicle-GNP; Biological: LD PepGNP-Dengue; Biological: HD vehicle-GNP; Biological: HD PepGNP-DengueSponsors: Emergex Vaccines Holding Ltd.; Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland; University of Lausanne HospitalsRecruiting

Prospective Study on the Risks of Dengue Fever for the Fetus.

Mar 30, 2021 | 18:00 pm

Condition: Dengue FeverIntervention: Other: data collectionSponsor: Centre Hospitalier Universitaire de la RéunionRecruiting

ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)

Mar 8, 2021 | 18:00 pm

Condition: DengueIntervention: Biological: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)Sponsors: University of Maryland, Baltimore; United States Army Medical Materiel Development Activity; Medical Technology Enterprise Consortium (MTEC)Completed

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)

Oct 22, 2020 | 18:00 pm

Condition: Dengue FeverInterventions: Drug: Zanamivir; Other: PlaceboSponsors: George Washington University; Naval Medical Research Center; Hospital Infantil de Niño Jesús de Barranquilla (HINJ); Universidad Bosque; Allied Research SocietyNot yet recruiting

Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso

Oct 9, 2020 | 18:00 pm

Condition: DengueIntervention: Other: Dengue module and rapid diagnostic testsSponsors: Foundation for Innovative New Diagnostics, Switzerland; Ministry of Health, Burkina Faso; Terre des hommes, Burkina Faso & SwitzerlandRecruiting

Dengue 3 Human Infection Model (DENV-3)

Mar 6, 2020 | 18:00 pm

Condition: DengueIntervention: Biological: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)Sponsors: State University of New York - Upstate Medical University; Walter Reed Army Institute of Research (WRAIR); U.S. Army Medical Research and Development CommandRecruiting

Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan

Oct 21, 2019 | 18:00 pm

Condition: DengueInterventions: Biological: Tetravalent live attenuated dengue vaccine admixture TV005; Biological: PlaceboSponsors: National Taiwan University Hospital; Centers for Disease Control, TaiwanRecruiting

Clinical Trial of Diagnostic Tests and Clinical Algorithms for Dengue in Febrile Subjects in Endemic Areas in Colombia

Aug 21, 2019 | 18:00 pm

Condition: DengueIntervention: Diagnostic Test: Dengue calculatorSponsors: Lyda Osorio; COMFANDI CAJA DE COMPENSACION DEL VALLE DEL CAUCA; SISTEMA GENERAL DE REGALIAS CASANARE, SANTANDER VALLE DEL CAUCA; RED AEDESCompleted

Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil

May 23, 2019 | 18:00 pm

Condition: DengueIntervention: Biological: CYD-TDVSponsors: Albert B. Sabin Vaccine Institute; Pan American Health Organization; State of Parana/Health Department of Parana; Ministry of Health of Brazil; Centro de Estudos Augusto Leopoldo Ayrosa GalvãoCompleted

Expansion of a Dengue-1 Live Virus Human Challenge

Mar 11, 2019 | 17:00 pm

Condition: DengueIntervention: Biological: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)Sponsors: State University of New York - Upstate Medical University; Janssen Pharmaceutica N.V., Belgium; U.S. Army Medical Research and Development CommandCompleted

Combating Dengue With Innovative, Paradigm-shift-Strategies: Early Dengue Surveillance in Adult Aedes Mosquitoes

Jan 10, 2019 | 18:00 pm

Condition: DengueIntervention: Other: GOS trap and dengue NS1 antigen kitSponsors: Jonathan Liew Wee Kent; Petaling Jaya City Council, Malaysia; Selangor State Health Department, MalaysiaUnknown status

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults

Dec 11, 2018 | 18:00 pm

Condition: Dengue FeverIntervention: Biological: Tetravalent Dengue Vaccine (TDV)Sponsor: TakedaCompleted

Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults

Nov 19, 2018 | 18:00 pm

Condition: Dengue FeverIntervention: Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)Sponsor: TakedaCompleted

Pilot Study to Detect DENGUE Virus in Sperm

Aug 2, 2018 | 18:00 pm

Condition: DengueIntervention: Biological: blood, urine and semen sampleSponsor: University Hospital, ToulouseCompleted

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)

Nov 14, 2017 | 18:00 pm

Condition: DengueInterventions: Biological: Tetravalent Dengue Vaccine (TDV); Biological: PlaceboSponsor: TakedaCompleted

Applying Wolbachia to Eliminate Dengue

Feb 16, 2017 | 18:00 pm

Conditions: Dengue; Zika Virus Infection; Chikungunya FeverInterventions: Biological: Wolbachia-infected Aedes aegypti mosquitoes; Other: standard practice dengue controlSponsors: Gadjah Mada University; Monash University; The Tahija FoundationTerminated

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Dec 15, 2016 | 18:00 pm

Conditions: Dengue Fever; Dengue Hemorrhagic Fever; Human Papillomavirus DiseaseInterventions: Biological: CYD Dengue Vaccine; Biological: Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.Sponsor: Sanofi Pasteur, a Sanofi CompanyCompleted

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

Jul 6, 2016 | 18:00 pm

Conditions: Dengue Fever; Dengue Hemorrhagic FeverInterventions: Biological: CYD Dengue Vaccine (5 dose formulation); Biological: Placebo, NaCl 0.9%Sponsor: Sanofi Pasteur, a Sanofi CompanyCompleted

Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule

Dec 8, 2015 | 18:00 pm

Conditions: Dengue Fever; Dengue Hemorrhagic FeverInterventions: Biological: CYD Dengue Vaccine (5-dose formulation); Biological: Placebo, NaCl 0.9%Sponsor: Sanofi Pasteur, a Sanofi CompanyCompleted

Main Menu

Login Form

Related Links